Please login to the form below

Not currently logged in
Email:
Password:

hGH-CTP

This page shows the latest hGH-CTP news and features for those working in and with pharma, biotech and healthcare.

Pfizer/Opko's long-acting growth hormone misses mark in trial

Pfizer/Opko's long-acting growth hormone misses mark in trial

Previously forecast as a blockbuster product, hGH-CTP fails to show significant change. ... A greater percentage of subjects on hGH-CTP normalised serum concentrations of insulin-like growth factor-1 (IGF-1) compared to placebo," it said.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Collaboration, licence. 581. Opko Health / Pfizer. Long-acting hGH-CTP for growth hormone deficiency in adults and children (p3).

  • Pharma deals during December 2014 Pharma deals during December 2014

    This product, named hGH-CTP, was in the portfolio of Prolor Biotech which Opko acquired in August 2013 for $480m. ... for adult GHD but for paediatric GHD, the royalties will transition to gross profit sharing for both hGH-CTP and Pfizer's Genotropin.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....